Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,144 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Relapse/Recurrence Clear all
Completed Not applicable Interventional Results available

Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity

NCT01065571
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
carrageenan, dietary intervention with no-carrageenan diet
Dietary Supplement · Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 31, 2026, 5:03 PM EDT
Terminated Phase 3 Interventional Results available

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

NCT02366663
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
90-Yttrium Ibritumomab tiuxetan, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous Hematopoietic Stem Cell Transplant, Rituximab
Radiation · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 31, 2026, 5:03 PM EDT
Terminated Phase 2Phase 3 Interventional

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

NCT01774578
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
Interventions
Docetaxel, HyperAcute®-Lung Immunotherapy, Gemcitabine, Pemetrexed
Drug · Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
24
States / cities
Santa Rosa, California • Stamford, Connecticut • Gainesville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 31, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies

NCT01683149
View directory record Official record
Conditions
Solid Tumor
Interventions
Topotecan, Sorafenib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
3 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Los Angeles, California • Hartford, Connecticut • Wilmington, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 31, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

NCT00045006
View directory record Official record
Conditions
Cancer
Interventions
vorinostat
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 31, 2026, 5:03 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07248144, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
215
States / cities
Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 5:03 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

NCT05735184
View directory record Official record
Conditions
Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia
Interventions
Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine, Quizartinib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
44
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 31, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation

NCT02162758
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Dexlansoprazole, Dexlansoprazole Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Jacksonville, Florida • Chapel Hill, North Carolina • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 31, 2026, 5:03 PM EDT
Withdrawn Phase 1 Interventional

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

NCT04500548
View directory record Official record
Conditions
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Primary Central Nervous System Neoplasm, Xeroderma Pigmentosum
Interventions
Biospecimen Collection, Ipilimumab, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 31, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

NCT02484430
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent Adult Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
14
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 31, 2026, 5:03 PM EDT
Terminated Not applicable Interventional Results available

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

NCT00726830
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Spartanburg, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 31, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT01931787
View directory record Official record
Conditions
Recurrent Small Cell Lung Cancer
Interventions
6,8-bis(benzylthio)octanoic acid
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 31, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Home-based HIIT to Improve CRC Survivorship: Feasibility and Relationship With Novel Surrogate Biomarkers of CRC Recurrence

NCT04080414
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colonic Neoplasms, Colonic Cancer, Rectal Neoplasms, Rectal Cancer
Interventions
Home-based high-intensity interval training, Home-based moderate-intensity continuous exercise
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
19 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 31, 2026, 5:03 PM EDT
Terminated Not applicable Interventional Results available

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

NCT00255684
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
graft-versus-tumor induction therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of Rochester
Other
Eligibility
Up to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 31, 2026, 5:03 PM EDT
Completed No phase listed Observational

Management of New-Onset Postoperative Atrial Fibrillation

NCT01395836
View directory record Official record
Conditions
Atrial Fibrillation, Coronary Artery Disease, Post Operative Arrythmia
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 31, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT02101944
View directory record Official record
Conditions
Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Pelareorep
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Columbus, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 31, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

NCT00695409
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, carmustine, cytarabine, etoposide, melphalan, ASCT, yttrium Y 90 ibritumomab tiuxetan
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 31, 2026, 5:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases

NCT01421017
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions
Radiation, Imiquimod, Cyclophosphamide
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 31, 2026, 5:03 PM EDT
Withdrawn Phase 1 Interventional

Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT02861040
View directory record Official record
Conditions
Recurrent Adult Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Vincristine Sulfate Liposome, Volasertib
Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
2
States / cities
Palo Alto, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 31, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

NCT00615589
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Leukemia
Interventions
Fludarabine/Busulfan x 4 days, stem cell transplant
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 31, 2026, 5:03 PM EDT
Active, not recruiting No phase listed Observational

Prediction of Recurrence Among Low Risk Endometrial Cancer Patients

NCT04604613
View directory record Official record
Conditions
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions
Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Hysterectomy, Laboratory Biomarker Analysis, Lymph Node Mapping, Sentinel Lymph Node Biopsy
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 31, 2026, 5:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

NCT06536049
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab, Ibrutinib, Positron Emission Tomography
Procedure · Biological · Drug
Lead sponsor
Yazeed Sawalha
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Minneapolis, Minnesota • Columbus, Ohio • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 5:03 PM EDT
Withdrawn Phase 2 Interventional

Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer

NCT00694291
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sorafenib, Placebo
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 31, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

NCT02654990
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
9
States / cities
Fayetteville, Arkansas • Los Angeles, California • Fort Collins, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 31, 2026, 5:03 PM EDT